Bausch + Lomb Completes Acquisition Of Xiidra®
09/29/23, 6:46 PM
Industry
health care
manufacturing
medical device
biotechnology
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Company Info
Company info
Bausch + Lomb Corporation is a leading global eye health company committed to improving people’s vision. The company focuses on developing innovative products for vision correction, surgical procedures, and consumer eye care. It operates with a long-standing dedication to enhancing the visual health of patients worldwide. Bausch + Lomb is recognized for its advanced technology and quality in eye care solutions.